Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

13 trials with published results (21%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

6.6%

4 terminated out of 61 trials

Success Rate

88.2%

+1.7% vs benchmark

Late-Stage Pipeline

21%

13 trials in Phase 3/4

Results Transparency

43%

13 of 30 completed with results

Key Signals

13 with results88% success

Data Visualizations

Phase Distribution

49Total
Not Applicable (17)
Early P 1 (1)
P 1 (5)
P 2 (13)
P 3 (8)
P 4 (5)

Trial Status

Completed30
Recruiting9
Unknown9
Active Not Recruiting5
Not Yet Recruiting4
Terminated4

Trial Success Rate

88.2%

Benchmark: 86.5%

Based on 30 completed trials

Clinical Trials (61)

Showing 20 of 20 trials
NCT07568665Recruiting

Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy.

NCT07448363Not Yet Recruiting

Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica

NCT07487831Phase 4Not Yet RecruitingPrimary

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

NCT07441395Phase 2Recruiting

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

NCT03742414Phase 2Active Not Recruiting

Seal, Stopping Eczema and Allergy Study

NCT06024499Phase 2Active Not Recruiting

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

NCT07037901Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT04017520Active Not Recruiting

Breast Milk: Influence of the Micro-transcriptome Profile on Atopy in Children Over Time

NCT05704205Not ApplicableActive Not RecruitingPrimary

The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)

NCT04804605Phase 3CompletedPrimary

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

NCT04845620Phase 3CompletedPrimary

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

NCT04246372Phase 2Completed

Tofacitinib for Immune Skin Conditions in Down Syndrome

NCT06998056Phase 2CompletedPrimary

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

NCT07270965Not ApplicableNot Yet Recruiting

Moisturization and Skin Hydration Study

NCT03293030Phase 4Completed

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

NCT06004986Phase 4Recruiting

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

NCT03981926Not ApplicableCompletedPrimary

Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis

NCT06469385Phase 1Terminated

Topical ENS-002 for Atopic Dermatitis in Adults

NCT07121062Not Yet Recruiting

Validation Of A Parent Administered Symptom Score For Unsettled Infants (Every Baby is UnIQue)

NCT06855745Phase 2Recruiting

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.

Scroll to load more

Research Network

Activity Timeline